This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Coronavirus - SARS-CoV-2: Risk group and biosafety consensus for laboratory with infectious samples / Coronavírus - SARS-CoV-2: Classe de risco e consensos de biossegurança para laboratório com amostras infectantes
Preprint
in Portuguese
| SciELO Preprints
| ID: pps-399
Responsible library:
BR1.1
ABSTRACT
The pandemic outbreak of coronavirus 2 (SARS-CoV-2), which began in China, is still ongoing in Brazil and worldwide, with over than 4.0 million confirmed cases and 280,000 deaths after 4 months of the virus spreading. It is now the top-priority pathogen to be dealt with due to its high transmissibility, severe illness and associated mortality, absence of effective prophylactic and therapeutic measures with knowledge gaps in human epidemiology, immunity and pathogenesis. To meet the increasing demand of the diagnostic and clinical services, it is necessary to improve biosafety and expand laboratory capabilities since the existing laboratories and workers cannot meet the emerging demand. This article highlights the risk class and biosafety consensus of the minimum requirements for the SARS-COV-2 clinical and diagnostic laboratories, as well as, the prevention of the biorisk to the workers, avoiding accidental dissemination to their families and the community.
RESUMO
A pandemia do Coronavírus 2 (SARS-CoV-2), iniciada na China, e ainda em curso no Brasil e mundo afora, já registra mais de 4,0 milhões de casos confirmados e mais de 280 mil óbitos após 4 meses de dispersão do vírus. É no momento o patógeno de maior prioridade a ser tratado, por ter alta transmissibilidade, associado à graves doenças e mortalidade, assim como, ausência de medidas profiláticas e terapêuticas eficazes, limitados conhecimentos da epidemiologia, imunidade e patogênese humana. Para acompanhar à crescente demanda dos serviços clínicos e diagnósticos, é necessário aprimorar a biossegurança e expandir a capacidades dos laboratórios e profissionais. O artigo destaca a classe de risco e os consensos dos requisitos mínimos de biossegurança para atividades em laboratórios clínicos e diagnósticos com o SARS-COV-2, assim como, a prevenção de riscos biológicos aos profissionais, evitando disseminação acidental às famílias e à comunidade.
Full text:
Available
Collection:
Preprints
Health context:
SDG3 - Target 3D Strengthen the capacity for early warning, risk reduction and management of national and global health risks
/
SDG3 - Target 3.3 End transmission of communicable diseases
Health problem:
Biological Hazards
/
COVID-19
Database:
SciELO Preprints
Type of study:
Etiology study
/
Risk factors
Language:
Portuguese
Year:
2020
Document type:
Preprint
